TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3479839

Group type: EXPERIMENTAL
Intervention: Active drug period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total hip prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (NSAID) or analgesic trials
Number of subjects: 0
Study: 31857431

Group type: EXPERIMENTAL
Intervention: Adavosertib (110 mg/m2) with Irinotecan (90 mg/m2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adavosertib (85 mg/m2) with Irinotecan (90 mg/m2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adavosertib (not specified) with Irinotecan (not specified)
Number of subjects: 37
Study: 30544376

Group type: EXPERIMENTAL
Intervention: ETView double-lumen tube (VDT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ETView single-lumen tube (VST)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Traditional double lumen tube (DT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ETView tubes (VDT/VST)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Postoperative outcomes
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ETView single lumen endotracheal tube
Number of subjects: 83
Study: 26841085

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (200 or 2000 IU/day)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 25796155

Group type: EXPERIMENTAL
Intervention: Shengjie Tongyu granules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tongxinluo capsule (control)
Number of subjects: 0
Study: 23782950

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 μg once daily for 24 to 30 months)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Standard treatment with anti‐thyroid drugs
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 492
Study: 21112881

Group type: EXPERIMENTAL
Intervention: Continuous interscalene ropivacaine 0.2% 2 ml h⁻¹ with mandatory 6 hourly boluses
Number of subjects: 81

Group type: COMPARATOR
Intervention: Continuous interscalene ropivacaine 0.2% 5 ml h⁻¹ with PRN boluses
Number of subjects: 81
Study: 19026248

Group type: EXPERIMENTAL
Intervention: Paroxetine CR 12.5 mg
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Paroxetine CR 25 mg
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study: 16772525

Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% oxygen) during isometric exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxia (21% oxygen) during isometric exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperoxia (100% oxygen) at rest
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postexercise circulatory arrest (PE-CA) after isometric exercise in hyperoxia
Number of subjects: 12
Study: 14704300

Group type: EXPERIMENTAL
Intervention: Iron supplementation (160 mg of ferrous sulfate, 50 mg elemental iron, twice daily; total of 320 mg ferrous sulfate, 100 mg elemental iron daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Average American diet (AAD)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Step 2 diet
Number of subjects: 26
Study: 11379897

Group type: EXPERIMENTAL
Intervention: self-care/NSAID
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: occlusal appliance/jaw mobilization + self-care/NSAID
Number of subjects: 69

Group type: COMPARATOR
Intervention: control group
Number of subjects: 69
Study: 9366499

Group type: EXPERIMENTAL
Intervention: Testosterone propionate (200mg TP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10172265

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study: 2424341

Group type: EXPERIMENTAL
Intervention: Prophylactic corticosteroid and/or antihistamine pretreatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prophylactic corticosteroid pretreatment
Number of subjects: 50
Study: 29406184

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 201

Group type: COMPARATOR
Intervention: Face mask (in patients treated by NIV prior to randomisation)
Number of subjects: 201
Study: 27321986

Group type: EXPERIMENTAL
Intervention: Simulation-based teaching via the Orpheus simulator (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Lecture-based teaching (n = 8)
Number of subjects: 17
Study: 24730564

Group type: EXPERIMENTAL
Intervention: Descriptive norm message
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Injunctive norm message
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: Descriptive and injunctive norm message
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Control messages (two types)
Number of subjects: 1020
Study: 23462072

Group type: EXPERIMENTAL
Intervention: Geographically targeted AdWords
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adverts placed on local websites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (AdWords and local website links)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 20837662

Group type: EXPERIMENTAL
Intervention: Cognitive dual-task training (five sessions, spaced at least 2 days apart)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 20
Study: 18227177

Group type: EXPERIMENTAL
Intervention: Vancomycin >=4 g/day
Number of subjects: 246

Group type: COMPARATOR
Intervention: Vancomycin <4 g/day
Number of subjects: 246

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 246
Study: 15624093

Group type: EXPERIMENTAL
Intervention: 20-25% of total energy derived from fat
Number of subjects: 25

Group type: COMPARATOR
Intervention: 40-45% of total energy derived from fat
Number of subjects: 25
Study: 12679620

Group type: EXPERIMENTAL
Intervention: Peripheral neurostimulation by posterior tibial nerve stimulation using a Stoller Afferent Nerve Stimulator (UroSurge, Coralville, Iowa, USA). Stimulation parameters: 0.5-10 mA, 200 micros, 20 Hz, performed every other day for 4 weeks.
Number of subjects: 32
Study: 10232634

Group type: EXPERIMENTAL
Intervention: Retinol (7576 retinol equivalents or 25000 IU)
Number of subjects: 2297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2297
Study: 8610833

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 20
Study: 1932300

Group type: EXPERIMENTAL
Intervention: Standard IVIG (Sandoglobulin, 0.1 mg/kg IgM)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: IgM-enriched IVIG (Pentaglobin, 30 mg/kg IgM)
Number of subjects: 2
Study: 6361988

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Acyclovir (active)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Acyclovir prodrug (BW 134U)
Number of subjects: 2
Study: 30789491

Group type: EXPERIMENTAL
Intervention: Nurse-led motivational telephone follow-up
Number of subjects: 294
Study: 28193267

Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced computed tomography (nCT)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Ultrasound sonography (US)
Number of subjects: 566
Study: 27221237

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including antenatal corticosteroids (ACS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 24384505

Group type: EXPERIMENTAL
Intervention: tDCS (right prefrontal‐‐anodal, left supraorbital‐‐cathodal) for 20 min at 1 mA current intensity
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 74
Study: 22397986

Group type: EXPERIMENTAL
Intervention: Patients with postthoracotomy pain (75 patients)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patients without postthoracotomy pain (35 patients)
Number of subjects: 110
Study: 19411614

Group type: EXPERIMENTAL
Intervention: Active drug treatment (exact drug not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progressing cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonprogressing cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline elevated triglycerides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline decreased peroneal motor NCV
Number of subjects: 0
Study: 17679784

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15658650

Group type: EXPERIMENTAL
Intervention: Decoction of Qingre Huoxue recipe (QHR) given one dose per day in addition to standard treatment.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard treatment including impact therapy of methyl-prednisolone followed by oral prednisone, with additional cyclophosphamide or mycophenolate mofetil for some patients.
Number of subjects: 32
Study: 11699672

Group type: EXPERIMENTAL
Intervention: High Affect Mirroring (HAM) group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Low Affect Mirroring (LAM) group
Number of subjects: 41
Study: 9021434

Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8206111

Group type: EXPERIMENTAL
Intervention: Pyridostigmine, 120 mg p.o.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neostigmine, 10 micrograms/kg i.v.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Physostigmine, 12.5 micrograms/kg i.v.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pyridostigmine, 120 mg p.o. (GHRH stimulated)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neostigmine, 10 micrograms/kg i.v. (GHRH stimulated)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Physostigmine, 12.5 micrograms/kg i.v. (GHRH stimulated)
Number of subjects: 36
Study: 3382764

Group type: EXPERIMENTAL
Intervention: Tamoxifen at a dose of 10 mg twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prednisolone at a dose of 5 mg twice a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ovarian irradiation
Number of subjects: 60
Study: 30467695

Group type: EXPERIMENTAL
Intervention: Niaoduqing Particles (5 g thrice daily and 10 g before bedtime for 24 weeks)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Niaoduqing Particles (after open-label treatment)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo (after open-label treatment)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Niaoduqing Particles
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Niaoduqing Particles (projected long-term effect)
Number of subjects: 292
Study: 28460246

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (COPE)
Number of subjects: 51
Study: 25857594

Group type: EXPERIMENTAL
Intervention: Tratinterol hydrochloride tablets
Number of subjects: 223

Group type: COMPARATOR
Intervention: Procaterol hydrochloride tablets (control)
Number of subjects: 223
Study: 23435521

Group type: EXPERIMENTAL
Intervention: C‐Port xA® System
Number of subjects: 71

Group type: COMPARATOR
Intervention: Hand-sewn technique
Number of subjects: 71

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 71
Study: 21649522

Group type: EXPERIMENTAL
Intervention: Bepotastine besilate ophthalmic solution 1.5%
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Bepotastine besilate ophthalmic solution 1.0%
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 18164473

Group type: EXPERIMENTAL
Intervention: Various nonsurgical interventions for CLBP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study: 15141794

Group type: COMPARATOR
Intervention: Bag-valve device
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Oxylator
Number of subjects: 104
Study: 11890637

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Iron supplementation during menstruation
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 10360290

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 286

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 286

Group type: COMPARATOR
Intervention: ASPRK
Number of subjects: 286
Study: 7812991

Group type: EXPERIMENTAL
Intervention: 125 mg oral clomipramine daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 75 mg oral clomipramine daily
Number of subjects: 33
Study: 2696914

Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional Surgery
Number of subjects: 16
Study: 65126

Group type: EXPERIMENTAL
Intervention: Immune serum globulin (20 ml)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 31567325

Group type: EXPERIMENTAL
Intervention: Intrathecal Drug Delivery Systems (IDDS)
Number of subjects: 1403
Study: 30574857

Group type: EXPERIMENTAL
Intervention: Probiotics (test group, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group, n=20)
Number of subjects: 40
Study: 29714858

Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping after pulsation loss
Number of subjects: 338

Group type: COMPARATOR
Intervention: Early clamping within 60 seconds after birth
Number of subjects: 338
Study: 25069638

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 198
Study: 23234632

Group type: EXPERIMENTAL
Intervention: Denosumab (180 mg subcutaneous every 4 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Denosumab (180 mg subcutaneous every 12 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous bisphosphonates
Number of subjects: 50
Study: 21319139

Group type: EXPERIMENTAL
Intervention: Tecnis Z9003 IOL
Number of subjects: 60

Group type: COMPARATOR
Intervention: AR40e IOL
Number of subjects: 60
Study: 18812411

Group type: EXPERIMENTAL
Intervention: Resilience-enhancing programme in Health Promoting Schools (HPS)
Number of subjects: 5510

Group type: COMPARATOR
Intervention: Non-Health Promoting Schools (non-HPS)
Number of subjects: 5510
Study: 16886144

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Metronidazole and Rifampin
Number of subjects: 39
Study: 15539971

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and beta blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone blocking agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study: 12498513

Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 1289

Group type: COMPARATOR
Intervention: Calcium dobesilate
Number of subjects: 1289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1289
Study: 9646192

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 240 mg twice daily
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 120 mg nightly
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg nightly
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 8252890

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 92

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 92
Study: 3612896

Group type: EXPERIMENTAL
Intervention: Activated charcoal (10 g as SuperCharR suspension) administered 2 hr prior, and at 0, 2, 6, and 8 hr after tobramycin administration.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (no activated charcoal treatment).
Number of subjects: 5
Study: 31199180

Group type: EXPERIMENTAL
Intervention: belimumab 10 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 28685495

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 10 mg metformin (T1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 50 mg metformin (T2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 500 mg metformin (T3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 1 mg furosemide (T4)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin combined with 5 mg furosemide (T5)
Number of subjects: 18
Study: 27782861

Group type: EXPERIMENTAL
Intervention: Acupuncture (eight pragmatic Traditional Chinese Medicine treatments over 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 15
Study: 24650076

Group type: EXPERIMENTAL
Intervention: Feeding tubes in nursing home residents with cognitive impairment
Number of subjects: 3479
Study: 22079009

Group type: EXPERIMENTAL
Intervention: Prenatal screening test offer
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Counseling regarding the meaning of testing
Number of subjects: 111
Study: 20572421

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (MAE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (CTR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise (HAE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance exercise (MRE)
Number of subjects: 48
Study: 18242413

Group type: EXPERIMENTAL
Intervention: Romiplostim (subcutaneous injections, adjusted doses to maintain platelet counts of 50x10(9)/L to 200x10(9)/L)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 16270114

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (five-contact, eight-week intervention)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 124
Study: 11860969

Group type: EXPERIMENTAL
Intervention: 0.25% pilocarpine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.125% pilocarpine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.0313% pilocarpine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.0625% pilocarpine
Number of subjects: 20
Study: 10199862

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 microgram/day)
Number of subjects: 18
Study: 7598670

Group type: EXPERIMENTAL
Intervention: Positive social behavior
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Negative social behavior
Number of subjects: 64
Study: 2162867

Group type: EXPERIMENTAL
Intervention: Fibre-containing feed (Enrich)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Fibre-free feed (Ensure)
Number of subjects: 91
Study: 20671

Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 30239421

Group type: EXPERIMENTAL
Intervention: Late peak of HMGB1
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Late peak of HMGB1 with inflammatory disease
Number of subjects: 210
Study: 28622891

Group type: EXPERIMENTAL
Intervention: Robot-assisted neck dissection (38 patients)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional neck dissection (75 patients)
Number of subjects: 113
Study: 25624387

Group type: EXPERIMENTAL
Intervention: 0.2‐0.5 mg/kg oral morphine
Number of subjects: 91

Group type: COMPARATOR
Intervention: 10 mg/kg of oral ibuprofen
Number of subjects: 91
Study: 23520456

Group type: EXPERIMENTAL
Intervention: Higher completed level of schooling (intervention group)
Number of subjects: 986

Group type: COMPARATOR
Intervention: Lower completed level of schooling (control group)
Number of subjects: 986
Study: 21677052

Group type: EXPERIMENTAL
Intervention: High fructose (HF) - 80 g fructose/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High sucrose (HS) - 80 g sucrose/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Medium fructose (MF) - 40 g fructose/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Medium glucose (MG) - 40 g glucose/d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High glucose (HG) - 80 g glucose/d
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dietary advice to consume low amounts of fructose
Number of subjects: 29
Study: 19434759

Group type: EXPERIMENTAL
Intervention: Combination treatment of bronchial arterial infusion (BAI) and rAd‐p53
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (only BAI)
Number of subjects: 58
Study: 16425970

Group type: EXPERIMENTAL
Intervention: Nifedipine Sandoz retard 30 after high-fat American breakfast
Number of subjects: 28

Group type: COMPARATOR
Intervention: Adalat OROS 30 after high-fat American breakfast
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nifedipine Sandoz retard 30 after fasting
Number of subjects: 28

Group type: COMPARATOR
Intervention: Adalat OROS 30 after fasting
Number of subjects: 28
Study: 14747675

Group type: EXPERIMENTAL
Intervention: H(2)-reduced (58)Fe with 3 mg/100 g in tortillas
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: H(2)-reduced (58)Fe with 3 mg/100 g in tortillas plus Na(2)EDTA at a ratio of 1:2 mol/mol
Number of subjects: 12
Study: 11349181

Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain
Number of subjects: 483
Study: 10966700

Group type: COMPARATOR
Intervention: 1.5 mL/kg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 2.0 mL/kg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 2.5 mL/kg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Fixed dose of 100 mL
Number of subjects: 221
Study: 8990639

Group type: EXPERIMENTAL
Intervention: Magnet retention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Stud retention
Number of subjects: 25
Study: 1620810

Group type: EXPERIMENTAL
Intervention: Filtered coffee (6 cups/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Boiled coffee (6 cups/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No coffee (abstinence from caffeine)
Number of subjects: 64
Study: 6370975

Group type: EXPERIMENTAL
Intervention: Nomifensine (100‐200 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0